Woman Given Weeks to Live Gets Christmas Early Thanks to Community: 'We Had to Do This'
A Virginia community has brought Christmas early to a woman with amyotrophic lateral sclerosis (ALS), who has just weeks to ...
Woman, 29, Discovers Through Genetic Testing She Will One Day Develop ALS: 'Don't Really Think It's Hit Me Yet' (Exclusive)
Lee Wilson discovered she has a "100%" chance of developing ALS, after losing her father and grandmother to the disease ...
News Medical on MSN4d
Answer ALS releases world's largest ALS patient-based iPSC and bio data repository
In a landmark continuing collaboration, Answer ALS and Cedars-Sinai have announced the completed availability of the largest ...
Daily Express US on MSN13d
Stephen Hawking issued a warning about an end of the world threat before he died
Stephen Hawking once warned against the imminent threat that artificial intelligence poses against humanity. "The development ...
Senior Housing News1d
Trace Neuroscience Nets $101M in Series A Funding for ALS, Dementia Therapy Development
The company’s lead therapeutic effort is aimed at improving the muscle function in people living with amyotrophic lateral ...
Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association
ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord, ultimately leading to muscle weakness and paralysis. ALS is an orphan disease, but its ...
FierceBiotech7d
Third Rock-backed Trace uses $101M series A to go after same ALS target as Lilly
Almost all cases of ALS and half of frontotemporal dementia (FTD) cases are linked to dysfunction in a protein TDP-43.
PharmiWeb1d
PLL Therapeutics obtains authorization to start phase I/II trial in Australia for patients with Amyotrophic Lateral Sclerosis (ALS)
today announces it will start a phase I/II clinical study in Australia for patients with Amyotrophic Lateral Sclerosis (ALS). The launch of this ALS study follows the recent approval by the Australian ...
Business Wire7d
Trace Neuroscience Launches With $101 Million Series A Financing to Expand Genomic Medicine for Neurodegenerative Diseases
Trace Neuroscience Launches with $101 Million Series A Financing to Expand Genomic Medicine for Neurodegenerative Diseases, ...
Stockhead on MSN1d
Preclinical studies confirm potential of Neurizon’s lead drug to treat ALS
Special Report: Clinical-stage biotech Neurizon Therapeutics has released positive results of preclinical studies confirming ...
Finanznachrichten20h
Neurizon Therapeutics Limited: Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study
Positive preclinical results in human in vitro iPSC Motor Neuron models of Amyotrophic Lateral Sclerosis (ALS) Neurizon's lead drug NUZ-001 and its major active metabolite significantly and ...